Steil Received Pharma Funds Before Key Votes
The congressman accepted campaign contributions from lobbyists shortly before taking positions on pharmaceutical legislation.
Updated on Sept. 25, 2026 in Diabetes
Live Poll
Do you believe campaign donations from lobbyists influence the voting decisions of members of Congress?
Representative Bryan Steil accepted nearly $220,000 in campaign funds from the pharmaceutical industry throughout his career. Records show he received donations from lobbyists shortly before casting votes on significant industry-related bills.
Why it matters
These financial ties raise questions regarding the alignment of legislative priorities with campaign funding from interest groups. Such patterns highlight the ongoing debate over the influence of industry money on federal policy decisions.
Official campaign finance records indicate Bryan Steil accepted $220,000 in pharmaceutical industry funds. This total includes a $500 contribution from lobbyist Dan Todd and a $1,500 donation from lobbyist Robert Wood.
The players
Bryan Steil
He is a U.S. Representative currently serving in Congress.
Dan Todd
He is a lobbyist who provided a campaign contribution to Representative Steil.
Robert Wood
He is a lobbyist who contributed to Representative Steil's campaign in 2022.
The details
Steil received a $500 donation from lobbyist Dan Todd on July 1, 2025, just two days before he voted for the One Big Beautiful Bill, which included an $8.8 billion provision for pharmaceutical companies. In 2022, he received $1,500 from lobbyist Robert Wood on the same day he voted against the Affordable Insulin Now Act.
Timeline
March 31, 2022: Steil received $1,500 from a lobbyist and voted against the Affordable Insulin Now Act.
July 1, 2025: Steil received a $500 donation from lobbyist Dan Todd.
July 3, 2025: Steil voted for the One Big Beautiful Bill, which contained an $8.8 billion pharmaceutical provision.
Health Landscape
This report follows a pattern set by the Affordable Insulin Now Act, where legislative outcomes regarding drug pricing are closely examined against industry lobbying efforts. The representative's voting history marks a departure from efforts to limit insulin costs through federal intervention.
Legislative decisions on pharmaceutical bills directly influence the availability and cost of treatments like insulin for local residents. These financial records help constituents understand how lobbying activity may shape their future access to affordable medication.
The takeaway
Understanding the financial backing of elected officials is essential for voters evaluating how their representatives address healthcare affordability. Residents should monitor future legislative sessions to see if these trends in campaign funding continue to influence drug policy.
Further reading
For more information on the legislative impact of drug policy, visit the Diabetes section.
Source note: This article includes information reported by The Milwaukee Courier.
Live Poll
Do you believe campaign donations from lobbyists influence the voting decisions of members of Congress?
